Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions"

Journal of Vascular Surgery

Volumn 48, Issue 5, 2008, Pages 1357-

  Dindyal, Shiva ^a   Sharma, Paritosh ^a   Kyriakides, Constantinos ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ANGIOPLASTY; ARTERY LESION; DRUG EFFECT; ENDOVASCULAR SURGERY; HUMAN; LEG AMPUTATION; LETTER; PRIORITY JOURNAL; RESTENOSIS; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; FEMALE; FEMORAL ARTERY; HUMANS; MALE; POPLITEAL ARTERY; RECURRENCE; RESEARCH DESIGN; TETRAZOLES; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 55049111585     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.06.070     Document Type: Letter

References (4)

1. Iida O., Nanto S., Uematsu M., Morozumi T., Kitakaze M., and Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 48 (2008) 144-149
2. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 suppl 1 (2007) S1-S75
3. Ebrahimi R., Saleh J.R., Toggart E.J., Hayatdavoudi B., Wolf C.J., Wadhani N.N., et al. Lipid-lowering therapy in patients with peripheral arterial disease. J Cardiovasc Pharmacol Ther 9 (2004) 271-277
4. Alnaeb M.E., Alobaid N., Seifalian A.M., Mikhailidis D.P., and Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 20 (2006) 696-705